Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 37Gastrointestinal 19Thoracic 11Tumor-Agnostic 9Other hematologic neoplasm 6Head & Neck 5CNS 5Breast 5Sarcoma 3Plasma cell 3Other solid neoplasm 3Endocrine 3Myeloid 2Gynecologic 2Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasms 1Endometrial Neoplasms 1Endometrial Adenocarcinoma 1

Interventions

Paclitaxel 264Carboplatin 246Cisplatin 153Bevacizumab 104Gemcitabine 78Topotecan 77liposomal doxorubicin 67pembrolizumab 60Docetaxel 56Cyclophosphamide 50Taxes 48Radiotherapy 44olaparib 43Surveys and Questionnaires 43Doxorubicin 43Filgrastim 42Brachytherapy 37Drug Therapy 31niraparib 28Blood Specimen Collection 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 26human papillomavirus vaccine, L1 type 16, 18 24Peripheral Blood Stem Cell Transplantation 23atezolizumab 22Oxaliplatin 22Pemetrexed 21Nivolumab 21Hyperthermic Intraperitoneal Chemotherapy 21Etoposide 21Immunoglobulin G 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × trametinib × Gynecologic × Clear all
NCT01935973 2020-10-14

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

National Cancer Institute (NCI)

Phase 1 Completed
26 enrolled
Gynecologic

Endometrial Adenocarcinoma

NCT01138085 2017-11-13

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

GlaxoSmithKline

Phase 1 Completed
240 enrolled
BreastGynecologic

Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡